Literature DB >> 28587819

Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABAA receptors.

Rebecca S Benham1, Nishani B Hewage2, Raymond F Suckow3, Elif Engin4, Uwe Rudolph5.   

Abstract

Deficits in neuronal inhibition via gamma-aminobutyric acid (GABA) type A receptors (GABAA-Rs) are implicated in the pathophysiology of major depressive disorder and the therapeutic effects of current antidepressant treatments, however, the relevant GABAA-R subtype as defined by its alpha subunit is still unknown. We previously reported anxiety- and depressive-like behavior in alpha2+/- and alpha2-/- mice, respectively (Vollenweider, 2011). We sought to determine whether this phenotype could be reversed by chronic antidepressant treatment. Adult male mice received 4 or 8mg/kg fluoxetine or 53mg/kg desipramine in their drinking water for four weeks before undergoing behavioral testing. In the novelty suppressed feeding test, desipramine had anxiolytic-like effects reducing the latencies to bite and to eat the pellet in both wild-type and alpha2+/- mice. Surprisingly, 4mg/kg fluoxetine had anxiogenic-like effects in alpha2+/- mice increasing latency to bite and to eat while 8mg/kg fluoxetine increased the latency to eat in both wild-type and alpha2+/- mice. In the forced swim and tail suspension tests, chronic desipramine treatment increased latency to immobility in wild-type and alpha2-/- mice. In contrast, chronic fluoxetine treatment increased immobility in alpha2-/- mice in both tasks while generally having no effect in wild-type mice. These findings suggest that in preclinical paradigms of anxiety and behavioral despair the antidepressant-like effects of desipramine are independent of alpha2-containing GABAA-Rs, while a reduction in alpha2 expression leads to an increased sensitivity to anxiogenic- and prodepressant-like effects with chronic fluoxetine treatment, pointing to a potential role of alpha2-containing GABAA-Rs in the response to serotonin-selective antidepressants.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Behavioral despair; Desipramine; Fluoxetine; Gabra2

Mesh:

Substances:

Year:  2017        PMID: 28587819      PMCID: PMC5551052          DOI: 10.1016/j.bbr.2017.05.063

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  36 in total

1.  Repeated neonatal handling with maternal separation permanently alters hippocampal GABAA receptors and behavioral stress responses.

Authors:  Fu-Chun Hsu; Guo-Jun Zhang; Yogendra Sinh H Raol; Rita J Valentino; Douglas A Coulter; Amy R Brooks-Kayal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants.

Authors:  Pablo Méndez; Antonio Pazienti; Gabor Szabó; Alberto Bacci
Journal:  J Neurosci       Date:  2012-11-21       Impact factor: 6.167

Review 4.  Electrophysiology of GABAA and GABAB receptor subtypes.

Authors:  J Bormann
Journal:  Trends Neurosci       Date:  1988-03       Impact factor: 13.837

5.  gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression.

Authors:  Qiuying Shen; Rachnanjali Lal; Beth A Luellen; John C Earnheart; Anne Milasincic Andrews; Bernhard Luscher
Journal:  Biol Psychiatry       Date:  2010-07-01       Impact factor: 13.382

6.  Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.

Authors:  Adolfo Sequeira; Firoza Mamdani; Carl Ernst; Marquis P Vawter; William E Bunney; Veronique Lebel; Sonia Rehal; Tim Klempan; Alain Gratton; Chawki Benkelfat; Guy A Rouleau; Naguib Mechawar; Gustavo Turecki
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

Review 7.  Depression: a case of neuronal life and death?

Authors:  Ronald S Duman
Journal:  Biol Psychiatry       Date:  2004-08-01       Impact factor: 13.382

8.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  Evidence for a role of GABAA receptor in the acute restraint stress-induced enhancement of spatial memory.

Authors:  Gang Zheng; Xueping Zhang; Yaoming Chen; Yun Zhang; Wenjing Luo; Jingyuan Chen
Journal:  Brain Res       Date:  2007-09-14       Impact factor: 3.252

10.  Association of childhood trauma exposure and GABRA2 polymorphisms with risk of posttraumatic stress disorder in adults.

Authors:  E C Nelson; A Agrawal; M L Pergadia; M T Lynskey; A A Todorov; J C Wang; R D Todd; N G Martin; A C Heath; A M Goate; G W Montgomery; P A F Madden
Journal:  Mol Psychiatry       Date:  2009-03       Impact factor: 15.992

View more
  2 in total

1.  α2-containing γ-aminobutyric acid type A receptors promote stress resiliency in male mice.

Authors:  Rebecca S Benham; Catherine Choi; Nathaniel W Hodgson; Nishani B Hewage; Rahel Kastli; Rachel J Donahue; John W Muschamp; Elif Engin; William A Carlezon; Takao K Hensch; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2021-08-18       Impact factor: 7.853

2.  Early-life adversity selectively impairs α2-GABAA receptor expression in the mouse nucleus accumbens and influences the behavioral effects of cocaine.

Authors:  Scott J Mitchell; Edward P Maguire; Linda Cunningham; Benjamin G Gunn; Matthias Linke; Ulrich Zechner; Claire I Dixon; Sarah L King; David N Stephens; Jerome D Swinny; Delia Belelli; Jeremy J Lambert
Journal:  Neuropharmacology       Date:  2018-08-21       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.